Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Determinants of disease and disability in the elderly: The Rotterdam elderly study
1991
No health without mental health
2007 Standout
Computed Tomography — An Increasing Source of Radiation Exposure
2007 Standout
Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk
2005
Cost-Effectiveness of Prolonged Administration of a Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis Following Total Hip Replacement
1999
Parkinson's disease
2021 Standout
Varicella Zoster Viral Disease
1999
Severe Hypoglycemia and Risks of Vascular Events and Death
2010 Standout
Cost-effectiveness of Whole-Body CT Screening
2005
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
2011 Standout
The metabolic syndrome
2010 Standout
Long-Term Morbidity and Mortality of Overweight Adolescents
1992 Standout
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
2003 Standout
Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention
2002
Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals
2005
Diet, Lifestyle, and the Risk of Type 2 Diabetes Mellitus in Women
2001 Standout
Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
2004 Standout
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
2017 Standout
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
2005 Standout
Abdominal Aortic Aneurysms: Cost-effectiveness of Elective Endovascular and Open Surgical Repair
2002
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
2013 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
The economic costs of NIDDM
1992
Risk scoring in the assessment of cardiovascular risk
2006
Short-term Prognosis After Emergency Department Diagnosis of TIA
2000
Antiviral Therapy for Herpes Zoster: Randomized, Controlled Clinical Trial of Valacyclovir and Famciclovir Therapy in Immunocompetent Patients 50 Years and Older
2000
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
2007 StandoutNature
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
2007 Standout
Obesity
2005 Standout
Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C
2012 Standout
The metabolic syndrome
2005 Standout
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
2013 Standout
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis
2005
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
2002 Standout
Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment
2001
Global and societal implications of the diabetes epidemic
2001 StandoutNature
Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001
2003 Standout
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
2003 Standout
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
2009
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
2010
Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List
2008 Standout
A Randomized Trial Comparing Conventional and Endovascular Repair of Abdominal Aortic Aneurysms
2004 Standout
Rheumatoid arthritis
2010 Standout
Carotid-Artery Intima and Media Thickness as a Risk Factor for Myocardial Infarction and Stroke in Older Adults
1999 Standout
The burden and costs of chronic diseases in low-income and middle-income countries
2007 Standout
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
2004 Standout
Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α
2006 Standout
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
2011 Standout
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
Herpes Zoster
2013 Standout
Should the first priority in cardiovascular risk management be those with prior cardiovascular disease?
2008
Osteoarthritis
2019 Standout
Concept and usefulness of cardiovascular risk profiles
2004
Herpes Zoster
2002 Standout
Economic costs of obesity and inactivity
1999
70-year legacy of the Framingham Heart Study
2019
One Thousand Health-Related Quality-of-Life Estimates
2000
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
WEIGHT AS A RISK FACTOR FOR CLINICAL DIABETES IN WOMEN
1990
Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction
2003
3d Transition Metals for C–H Activation
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis
2009 Standout
2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
2003 Standout
Projection of the prevalence of Parkinson's disease in the coming decades: Revisited
2017
Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.
1999
Mitochondrial Dysfunction and Type 2 Diabetes
2005 StandoutScience
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
2010
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Aminoquinoline-directed, cobalt-catalyzed carbonylation of sulfonamide sp2 C–H bonds
2017
Presentation of multivariate data for clinical use: The Framingham Study risk score functions
2004
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
General Cardiovascular Risk Profile for Use in Primary Care
2008 Standout
Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance
2003 StandoutScience
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis
2015
Works of Daniel M. Huse being referenced
Cost effectiveness of HMG-CoA reductase inhibition in Canada.
2001
Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
2002
Cost-effectiveness of statins
1998
Cimetidine and adverse reactions: A meta-analysis of randomized clinical trials of short-term therapy
1989
Prevention of Deep-Vein Thrombosis following Total Hip Replacement Surgery with Enoxaparin versus Unfractionated Heparin: A Pharmacoeconomic Evaluation
1994
Burden of illness in Parkinson's disease
2005
Direct Medical Costs of Coronary Artery Disease in the United States 11This study was supported in part by Parke-Davis, a division of Warner-Lambert Company, Morris Plains, New Jersey, and Pfizer, Inc., New York, New York.
1998
Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia
1997
Primary and subsequent coronary risk appraisal: New results from The Framingham Study
2000
Cimetidine and adverse reactions: A meta-analysis of randomized clinical trials of short-term therapy☆
1989
Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis.
2003
Primary and subsequent coronary risk appraisal: New results from the Framingham study
2000
Selective 5-HT1A-R-agonist Repinotan Prevents Remifentanil-induced Ventilatory Depression and Prolongs Antinociception
2011
Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.
1994
The Economic Costs of Non—Insulin-Dependent Diabetes Mellitus
1989